Sign up
Pharma Capital

Dechra Pharmaceuticals makes bolt-on acquisition

It is paying £4.4mln or 2.4-times revenues for Caledonian Holdings
1538982727_shutterstock_532512499.jpg
The UK group is buying a New Zealand supplier to vets specialising in horses

Dechra Pharmaceuticals PLC (LON:DPH) has made a small bolt-on acquisition.

It is paying £4.4mln or 2.4-times revenues, for Caledonian Holdings, a New Zealand supplier to vets specialising in horses.

The deal will establish Dechra as a leading equine pharmaceutical supplier in both Australia and New Zealand, the company said.

"We are pleased to have acquired the trade and assets of Caledonian which will be integrated into our existing Australian and New Zealand businesses. This will enable Dechra to leverage its position in the ANZ equine market," said chief executive Ian Page.

 

Ian_55ae0ddd437b7.jpg


Register here to be notified of future DPH Company articles
View full DPH profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.